Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Myeloid 1

Conditions

Myelodysplastic Syndromes 4Leukemia 3Myeloproliferative Disorders 2Anemia, Refractory, with Excess of Blasts 2Myelodysplastic-Myeloproliferative Diseases 1Lymphoma, Extranodal NK-T-Cell 1Lymphohistiocytosis, Hemophagocytic 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Down Syndrome 1Anemia, Refractory 1

Interventions

asparaginase erwinia chrysanthemi recombinant 1Thioguanine 1Mitoxantrone 1Leyk 1Etoposide 1Daunorubicin 1Cytarabine 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Down Syndrome × Asparaginase × Myeloid × Clear all
NCT02521493 2025-08-01

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Children's Oncology Group

Phase 3 Active not recruiting
280 enrolled 13 charts
MyeloidOther hematologic neoplasm

Down Syndrome, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡